# US 2004/0082610 A1 · Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082610 A1
- Document ID: US20040082610A1
- Status: Published application
- Kind: A1
- Application number: 10/659,095
- Filed: 2003-09-10
- Published: 2004-04-29
- Earliest claimed: 2002-09-11
- Assignees: Aventis Pharma S.A.
- Inventors: Eric Bacque; Antony Bigot; Youssef El Ahmad; Jean-Luc Malleron; Serge Mignani; Baptiste Ronan; Michel Tabart; Fabrice Viviani
- Web page: https://patentgrep.com/patent/US20040082610A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 31/04: Antibacterial agents
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 409/14: containing three or more hetero rings
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Quinolylpropylpiperidine derivatives of general formula (I) in which R1a is hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino and R1b is hydrogen, or R1a and R1b form an oxo, R2 is carboxyl, carboxymethyl or hydroxymethyl, R3 is alkyl either substituted with phenylthio optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino, or with cycloalkylthio (3 to 7 members) optionally substituted with halogen or trifluoromethyl, or with heteroarylthio (5 to 6 members and 1 to 4 heteroatoms chosen from N, O and S), optionally substituted with halogen, hydroxyl, alkyl, alkoxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkoxycarbonyl, cyano or amino or R3 is propargyl substituted with phenyl or heteroaryl as defined above, R4 is alkyl, alkenyl-CH2— or alkynyl-CH2—, cycloalkyl or cycloalkylalkyl, in their various isomeric forms, separate or as mixtures, and also their salts, their preparation process and intermediates and the compositions containing them. These novel derivatives are potent antibacterial agents. 1

## Claims

### Claim 1

1) A compound of the formula (I):
18
wherein:
R1a is hydrogen, halogen, hydroxyl, amino, alkylamino, dialkylamino, hydroxyamino, alkoxyamino or alkylalkoxyamino; and
R1b is hydrogen; or
R1a and R1b form an oxo group;
R2 is carboxyl, carboxymethyl or hydroxymethyl;
R3 is C1-6alkyl substituted with phenylthio, C3-7cycloalkylthio or 5- to 6-membered heteroarylthio; or propargyl substituted with phenyl, C3-7cycloalkyl or 5- to 6-membered heteroaryl;
wherein said heteroaryl is having 1 to 4 heteroatoms chosen from nitrogen, oxygen and sulfur; and
wherein said phenyl or said heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, alkyl, alkyloxy, trifluoromethyl, trifluoromethoxy, carboxyl, alkyloxycarbonyl, cyano and amino; and
wherein said cycloalkyl is optionally substituted with one or more substituents chosen from halogen and trifluoromethyl; and
R4 is C1-6alkyl, C2-6alkenyl-CH2— or C2-6alkynyl-CH2—, C3-8cycloalkyl or C3-8cycloalkylalkyl; or
an isomer, an enantiomer, a diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

2) The compound as set forth in claim 1, wherein R1a is hydroxyl and R1b is hydrogen.

### Claim 3 (depends on 1)

3) The compound as set forth in claim 1, wherein R1a and R1b form an oxo group.

### Claim 4 (depends on 1)

4) The compound as set forth in claim 1, wherein R4 is C1-6alkyl.

### Claim 5 (depends on 1)

5) The compound as set forth in claim 1, wherein R2 is carboxyl.

### Claim 6 (depends on 1)

6) The compound as set forth in claim 1, wherein R3 is C1-6alkyl substituted with an optionally substituted phenylthio, cycloalkylthio or heteroarylthio.

### Claim 7 (depends on 6)

7) The compound as set forth in claim 6, wherein R3 is ethyl substituted with thienylthio or phenylthio substituted with halogen or cyclohexylthio or cyclopentylthio.

### Claim 8 (depends on 1)

8) The compound as set forth in claim 1, which is selected from the group consisting of:
4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)propyl]-1-[2-(2,5-difluorophenyl-sulfanyl)ethyl]piperidine-3-carboxylic acid; and
4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)propyl]-1-[2-(2-thienylsulfanyl)ethyl]piperidine-3-carboxylic acid; or
an isomer, an enantiomer, a diastereoisomer or a mixture thereof, or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

9) A process for preparing a compound of formula (I) as set forth in claim 1 comprising condensing R3-X with a compound of formula (II):
19
wherein R4 is as defined in claim 1;
R′1a is hydrogen or hydroxyl; and
R1b is hydrogen; or
R′1a and R1b form an oxo group; and
R′2 is protected carboxyl or carboxymethyl;
to obtain a compound of formula (III):
20
wherein R′1a, R1b, R′2, R3 and R4 are as defined above; and optionally
treating the compound of formula (III) in which R′1a is hydroxyl and R1b is hydrogen with a halogenating agent; or optionally
oxidizing the compound of formula (III) in which R′1a is hydroxyl and R1b is hydrogen to an oxo group; and
converting said oxo group to hydroxyimino or alkoxyimino group;
to obtain a compound of formula (IV):
21
wherein R′2, R3 and R4 are as defined above; and R5 is hydrogen or alkyl; and
reducing the compound of formula (IV) in which R5 is hydrogen to the corresponding amine; and optionally,
alkylating said amine to a monoalkylated or dialkylated amine; or optionally
reducing the compound of formula (IV) in which R5 is hydrogen to a hydroxylamine, or
reducing the compound of formula (IV) in which R5 is an alkyl to an alkoxyamine; and optionally
alkylating said alkoxyamine to obtain the corresponding compound in which R1a is alkylalkoxyamino; and
converting R′2 to carboxyl or carboxymethyl; and optionally
reducing said carboxyl or protected carboxyl compound to hydroxymethyl compound; and optionally
converting said hydroxymethyl compound to carboxymethyl compound; and optionally
separating the isomers, and removing the acid-protecting group; and optionally
converting said compound to a suitable salt.

### Claim 10 (depends on 9)

10) The process as set forth in claim 9, wherein the compound of formula (II), in which R′1a is hydroxyl, is prepared by oxidation in a basic medium of a corresponding compound for which R′1a and R1b are hydrogen, the amine functional group of the piperidine is protected and R′2 is as defined in claim 9.

### Claim 11 (depends on 9, 10)

11) The process as set forth in claim 9, wherein the compound of formula (II) in which R′1a and R1b form an oxo group is prepared by oxidation of a corresponding compound of formula (II) in which R′1a is a hydroxyl, which is obtained as described in claim 10.

### Claim 12 (depends on 1, 9)

12) The process as set forth in claim 9, wherein the compound of formula (II) in which R′2 represents a protected carboxymethyl, and R′1a and R1b are hydrogen, is prepared by condensing a suitable phosphorous ylide with a compound of formula (IX):
22
wherein Rz is an amino-protecting group; to obtain a compound of formula (VIII):
23
wherein Rz is as defined above and R″2 is a protected carboxyl; and condensing said compound of formula (VIII) with a compound of formula (VII):
24
wherein R4 is defined as in claim 1 and Hal represents an iodine or bromine atom; to obtain a compound of formula (VI):
25
wherein R″2 and Rz are as defined above; and subjecting said compound of formula (VI) to a selective hydrogenation; and optionally deprotecting, where appropriate, the amino group of the piperidine.

### Claim 13 (depends on 12)

13) The process as set forth in claim 12, wherein the compound of formula (II) in which R′2 is protected carboxyl is prepared by
subjecting a compound of formula (II) in which R′2 is protected carboxymethyl to a reduction to obtain a compound of formula (II) in which R′2 is hydroxyethyl;
converting said hydroxyethyl compound to a p-toluenesulfonyloxyethyl derivative; and
converting said derivative to a vinyl derivative by an elimination reaction; and
oxidizing said vinyl derivative and protecting thus obtained carboxyl to obtain compound of formula (II) in which R′2 is protected carboxyl.

### Claim 14 (depends on 8, 9, 10, 12)

14) The process as set forth in claim 9, wherein the compound of formula (II), in which R′1a and R1b are hydrogen atoms, is prepared by allyation of the keto ester of general formula (XIV):
26
wherein R′2 is as defined in claim 8 and Rz is as defined in claim 12, to obtain a derivative of general formula (XIII):
27
wherein R′2 and Rz are as defined above, which is reacted with an alkyl oxalyl halide to obtain a derivative of general formula (XII):
28
wherein R″ represents an alkyl and R′2 and Rz are as defined above, which is subjected to a deoxygenation reaction, to obtain a derivative of general formula (X):
29
in which R′2 and Rz are as defined above, which is condensed with a quinoline derivative of general formula (VII) as defined in claim 10, to obtain a derivative of general formula (XI):
30
and then the amino-protecting radical Rz is removed.

### Claim 15 (depends on 9)

15) The process as set forth in claim 9 wherein the compound formed is 4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2,5-difluoro-phenylsulfanyl)ethyl]piperidine-3-carboxylic acid.

### Claim 16 (depends on 9)

16) The process as set forth in claim 9 wherein the compound formed is 4-[3-hydroxy-3-(3-chloro-6-methoxyquinolin-4-yl)-propyl]-1-[2-(2-thienylsulfanyl))ethyl]piperidine-3-carboxylic acid.

### Claim 17 (depends on 1)

17) A pharmaceutical composition comprising therapeutically effective amount of a compound of formula (I) as set forth in claim 1 or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.

### Claim 18 (depends on 1)

18) A compound of formula (II):
31
wherein R4 is as defined in claim 1, either R′1a is hydrogen or hydroxyl and R1b is hydrogen or R′1a and R1b form an oxo group and R′2 is protected carboxyl or carboxymethyl.

### Claim 19 (depends on 1)

19) A compound of formula (A):
32
wherein R1a, R1b, R3 and R4 are as defined in claim 1 and R′2 is protected carboxyl or carboxymethyl.

### Claim 20 (depends on 1)

20) A compound of formula (IV):
33
wherein R3 and R4 are as defined in claim 1 and R′2 is protected carboxyl or carboxymethyl and R5 is hydrogen or alkyl.

### Claim 21 (depends on 1)

21) A compound of formula (VI):
34
wherein R4 is as defined in claim 1 and R″2 is protected carboxyl and Rz is an amino-protecting group.

### Claim 22 (depends on 1)

22) A compound of formula (XI):
35
wherein R4 is as defined in claim 1, R′2 is protected carboxyl or carboxymethyl and Rz is an amino-protecting group.

### Claim 23 (depends on 9, 12)

23) A compound of formulae:
36
wherein R′2 is as defined in claim 9 and R″2 and Rz are as defined in claim 12.

### Claim 24 (depends on 1)

24) A method of treatment of a bacterial infection in a patient comprising administering to said patient a therapeutically effective amount of a compound of formula (I) as set forth in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

25) The method as set forth in claim 24 wherein said bacterial infection is caused by gram (+) bacteria.

### Claim 26 (depends on 24)

26) The method as set forth in claim 24 wherein said bacterial infection is staphylococcic infection.

### Claim 27 (depends on 23)

27) The method as set forth in claim 23 wherein said staphylococcic infection is selected from the group consisting of staphylococcal septicemias, malignant staphylococcic infections of the face or skin, pyoderma, septic or suppurant wounds, anthrax, phlegmons, erysipelas, acute primary or post-influenza staphylococcic infections, bronchopneumonias and pulmonary suppurations.

### Claim 28 (depends on 23)

28) The method as set forth in claim 23 wherein said bacterial infection is colibacilloses and related infections, proteus infection, klebsiella infection, salmonella infection, and infection caused by gram (−) bacteria.
